Saturday, September 4, 2010

9/5 RegenMD

     
    RegenMD    
   
Evaluation of adipose-derived stromal vascular fraction or bone marrow-derived mesenchymal stem cells for treatment of osteoarthritis.
September 4, 2010 at 1:18 AM
 
Related Articles

Evaluation of adipose-derived stromal vascular fraction or bone marrow-derived mesenchymal stem cells for treatment of osteoarthritis.

J Orthop Res. 2009 Dec;27(12):1675-80

Authors: Frisbie DD, Kisiday JD, Kawcak CE, Werpy NM, McIlwraith CW

The purpose of this study was the assessment of clinical, biochemical, and histologic effects of intraarticular administered adipose-derived stromal vascular fraction or bone marrow-derived mesenchymal stem cells for treatment of osteoarthritis. Osteoarthritis was induced arthroscopically in the middle carpal joint of all horses, the contralateral joint being sham-operated. All horses received treatment on Day 14. Eight horses received placebo treatment and eight horses received adipose-derived stromal vascular fraction in their osteoarthritis-affected joint. The final eight horses were treated the in osteoarthritis-affected joint with bone marrow-derived mesenchymal stem cells. Evaluations included clinical, radiographic, synovial fluid analysis, gross, histologic, histochemical, and biochemical evaluations. No adverse treatment-related events were observed. The model induced a significant change in all but two parameters, no significant treatment effects were demonstrated, with the exception of improvement in synovial fluid effusion PGE2 levels with bone marrow-derived mesenchymal stem cells when compared to placebo. A greater improvement was seen with bone marrow-derived mesenchymal stem cells when compared to adipose-derived stromal vascular fraction and placebo treatment. Overall, the findings of this study were not significant enough to recommend the use of stem cells for the treatment of osteoarthritis represented in this model.

PMID: 19544397 [PubMed - indexed for MEDLINE]

   
   
CIRM Moves Ahead on $50 Million Clinical Trial Round
August 31, 2010 at 3:48 AM
 
   
   
Legislation to Give CIRM More Employees Goes to Governor
August 26, 2010 at 2:30 AM
 
   
   
CIRM's Sheehy Says CIRM to Pay Off in Cures and Economic Development
August 25, 2010 at 3:00 AM
 
   
   
California Radio Talk Show on hESC Ruling
August 24, 2010 at 1:34 PM
 
   
   
The Latest from the NIH re the hESC Ruling
August 24, 2010 at 12:59 PM
 
   
   
Media Coverage: Political and Research Implications of hESC Ruling
August 24, 2010 at 4:26 AM
 
   
   
CIRM Director Prieto Says hESC Research Ruling 'Almost Beyond Belief'
August 23, 2010 at 2:25 PM
 
   
   
California Stem Cell Agency Deplores Ruling Nixing Fed hESC Research
August 23, 2010 at 1:19 PM
 
   
   
The $3 Billion Question: Kids, Scientists and CIRM
August 22, 2010 at 8:54 AM
 
   
   
Correction
August 20, 2010 at 3:30 AM
 
   
   
Massive, $243 Million Disease Round Gets Okay from Stem Cell Agency
August 19, 2010 at 11:42 AM
 
   
   
CIRM Board Meeting Underway
August 19, 2010 at 6:19 AM
 
   
   
Today's Board Meeting Coverage Cancelled; Tomorrow's Still On
August 18, 2010 at 5:08 AM
 
   
   
Coverage of Today's Stem Cell Board Meeting
August 18, 2010 at 4:46 AM
 
   
   
Belated Info on Election of New CIRM Chair, $120 Million Grant Round and Costly CIRM Study
August 17, 2010 at 10:42 AM
 
   
   
CIRM Hiring of Former Geron Exec Raises Conflict of Interest Questions
August 17, 2010 at 1:51 AM
 
   
   
Bad Link Fixed
August 16, 2010 at 12:16 PM
 
   
   
Economic Interest Statements of CIRM Directors Posted Online by California Stem Cell Report
August 15, 2010 at 7:35 AM
 
   
     
 
This email was sent to regenmd@gmail.com.
Delivered by Feed My Inbox
230 Franklin Road Suite 814 Franklin, TN 37064
Account Login
Unsubscribe Here Feed My Inbox
 
     

No comments: